About E3 ubiquitin-protein ligase TRIM15
E3 ubiquitin-protein ligase TRIM15 (TRIM15) is a protein
from Homo sapiens identified by UniProt accession
Q9C019, 465 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM15 |
| UniProt accession | Q9C019 |
| Gene | TRIM15 |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- low density lipoprotein cholesterol measurement · score 0.13
- neoplasm · score 0.09
- non-small cell lung carcinoma · score 0.09
- Barrett's esophagus · score 0.08
- hepatocellular carcinoma · score 0.07
- chronic obstructive pulmonary disease · score 0.07
- gastric adenocarcinoma · score 0.06
- melanoma · score 0.06
- Parkinson disease · score 0.06
- systemic lupus erythematosus · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9C019-F1 | alphafold | PREDICTED | 83.85 | — |
Amino-acid sequence (465 residues)
MPATPSLKVV HELPACTLCA GPLEDAVTIP CGHTFCRLCL PALSQMGAQS SGKILLCPLC QEEEQAETPM APVPLGPLGE TYCEEHGEKI YFFCENDAEF LCVFCREGPT HQAHTVGFLD EAIQPYRDRL RSRLEALSTE RDEIEDVKCQ EDQKLQVLLT QIESKKHQVE TAFERLQQEL EQQRCLLLAR LRELEQQIWK ERDEYITKVS EEVTRLGAQV KELEEKCQQP ASELLQDVRV NQSRCEMKTF VSPEAISPDL VKKIRDFHRK ILTLPEMMRM FSENLAHHLE IDSGVITLDP QTASRSLVLS EDRKSVRYTR QKKSLPDSPL RFDGLPAVLG FPGFSSGRHR WQVDLQLGDG GGCTVGVAGE GVRRKGEMGL SAEDGVWAVI ISHQQCWAST SPGTDLPLSE IPRGVRVALD YEAGQVTLHN AQTQEPIFTF TASFSGKVFP FFAVWKKGSC LTLKG
Explore E3 ubiquitin-protein ligase TRIM15 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets